Diagnosis and management of von Willebrand disease in Slovakia

Peter Kubisz, Juraj Sokol, Tomas Simurda, Ivana Plamenova, Miroslava Dobrotova, Pavol Holly, Ingrid Skornova, Jan Štasko

Background: Von Willebrand disease (VWD) is a common bleeding disorder with prevalence in the Slovak Republic of 11.2 cases per 100,000 people.

Methods: We conducted a retrospective audit of 610 VWD patients in Slovakia.

Results: Care of local patients with VWD primarily occurs through our comprehensive treatment centre, although some patients are managed solely by their primary care physician or community haematologist. Type 1 VWD is the most common subtype, with more females carrying this diagnosis than males. Diagnosis and treatment in general follows guidelines outlined by the European Group on VWD, British Committee for Standards in Haematology and Slovak Society on Haemostasis and Thrombosis. An ongoing study “Genetic Background and Haemostatic Changes in the Patients with VWD” is currently enrolling patients with all VWD subtypes across Slovakia in order to better delineate the extent of VWD and correlate bleeding symptoms with laboratory findings and von Willebrand factor (VWF) sequence variations.

Conclusions: VWD diagnosis and management is best performed through hematology specialists familiar with the complexities of this condition, such as those in the hemophilia treatment centres.

Keywords: Von Willebrand disease (VWD); diagnosis; management; Slovakia

Received: 02 October 2017; Accepted: 23 November 2017; Published: 01 February 2018.
doi: 10.21037/aob.2018.01.03

View this article at: http://dx.doi.org/10.21037/aob.2018.01.03

Introduction

Von Willebrand disease (VWD) is usually reported to be “the most common human inherited bleeding disorder”, actually found in approximately 1% of the general population (1-3). The disorder was first described in 1926 by Erik von Willebrand, who recognized that it differed from hemophilia and named it “hereditary pseudohemophilia” (4). The factor in plasma that corrects the disease was not identified until many years later and was called von Willebrand factor (VWF). VWF is a complex plasma protein with multiple functions, which overall contribute to the formation of a platelet thrombus at sites of injury to help prevent blood loss. VWF accomplishes this major haemostasis function by anchoring platelets to sites of vascular injury as well binding to factor VIII (FVIII), thus protecting FVIII from degradation and delivering it to sites of vascular injury (5,6). The disease is characterized mainly by mucosa-associated bleeding and bleeding after surgery and trauma. The diagnosis is based on a personal or family history of bleeding and laboratory evidence of abnormalities in VWF, factor VIII, or both. Affected patients essentially have reduced levels of functional VWF, and various types of VWD can be distinguished on the basis of phenotypic characteristics. Deficiency of VWF results in a bleeding disorder that varies in severity according to the degree of deficiency and the specific characteristics of the molecule (7,8). Clinical expression of VWD is usually mild in type 1, with increasing severity in type 2 and type 3. In general, the severity of bleeding correlates with
the degree of the reduction of VWF and FVIII. Mucocutaneous bleeding (epistaxis especially during childhood, easy bruising) is a typical, prominent manifestation of the disease and may affect the quality of life. However, the rate of spontaneous bleeding may be low even in patients with severe VWF deficiency (9). This review summarizes our management of patients with VWD in Slovakia based on the literature and our experience.

Methods
This study design is retrospective and observational. The population of VWD patients were recruited from a regional registry at the Martin University Hospital and National Registry of Congenital Bleeding Disorder at Bratislava University Hospital, which contain comprehensive demographic and clinical data. However, for scientific purposes data was then de-identified by the authors and handled in this manner. The regional registry is a database that accumulates clinical data about patients with coagulation disorders from all across Slovakia both for clinical and scientific purposes. As soon as a patient is diagnosed with bleeding disorder, he/she is being included in the registry.

Results

Organization of patients with VWD in Slovakia
The National Centre of Haemostasis and Thrombosis in Martin is one of the national haemophilia treatment centres in Slovakia. Together with the National Haemophilia Centre in Bratislava, our centre provides comprehensive care to patients with bleeding disorders. However, VWF multimer analysis and genetic testing is performed only in Martin. These two Slovakian centres provide services to more than 2,100 patients, both paediatric and adult, from all over Slovakia who have been diagnosed with a bleeding disorder. They offer state-of-the-art comprehensive clinical care, education to patients and their families, and accessibility to clinical research projects that are oriented to improving the lives of people with bleeding disorders. Additionally, 62 local haemophilia centres help to improve care of these patients at a regional level.

Epidemiology
Referral-based prevalence is the number of patients seen at specialized centres divided by the total population served.
by those centres. Figure 1 (per 100,000 inhabitants) shows prevalence ranging from 1.0 in Ukraine and Russia to 16.3 in the UK. The true prevalence of VWD is probably higher than suggested by available estimates, due to misdiagnosis or misrecognition of VWD. The referral-based prevalence per 100,000 inhabitants is 11.2 in Slovakia, a figure that is relatively high according to published referral-based prevalence around the world (10). The total Slovak population is 5,443,583 and the total number of patients with VWD in 2017 is 610 according to the National Registry of Congenital Bleeding Disorders in Slovakia, which is run by the National Haemophilia Centre, University Hospital and

<table>
<thead>
<tr>
<th>VWD type</th>
<th>Type 1</th>
<th>Type 2A</th>
<th>Type 2B</th>
<th>Type 2M</th>
<th>Type 2N</th>
<th>Type 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients (%)</td>
<td>397 [65]</td>
<td>124 (20.4)</td>
<td>18 (3.0)</td>
<td>8 (1.3)</td>
<td>12 (2.0)</td>
<td>51 (8.4)</td>
</tr>
</tbody>
</table>

VWD, von Willebrand disease.
Medical School of Comenius University in Bratislava. Type 1 patients represented 65% (n=397), type 2A 20.4% (n=124), type 2B 3.0% (n=18), type 2M 1.3% (n=8), type 2N 2.0% (n=12) and type 3 8.4% (n=51), see Table 1.

The world-wide prevalence figures for type 3 VWD vary substantially as shown in Figure 2 (10). It is surprising that Slovakia has one of the highest prevalence of VWD type 3 in the world.

The age distribution of patients with VWD is shown in Figure 3 (10). Age distribution is very similar around the world. Most patients are of working age.

The number of patients with HIV and hepatitis C is shown in Figure 4 (10). It is pleasing to state that Slovakia has no HIV affected VWD patient. Hepatitis C was diagnosed in 23 VWD patients.

**Diagnosis of VWD in Slovakia**

Diagnosis in general follows guidelines outlined by the European Group on VWD, British Committee for Standards in Haematology and Slovak Society on Haemostasis and Thrombosis (11,12). Diagnosis of VWD is primarily based on VWF antigen (VWF:Ag) and on the VWF ristocetin cofactor (VWF:RCo) activity assay. The laboratory at the National Centre of Haemostasis and Thrombosis in Martin provides factor VIII activity (FVIII:C), VWF:Ag, VWF:RCo, VWF collagen binding (VWF:CB) and VWF multimers together as a “VWD profile”. Blood type is also obtained, as VWF levels vary by blood type. Our centre also performs low-dose ristocetin-induced platelet aggregation in case of suspicion of type 2 VWD. As mentioned above, the National Centre of Haemostasis and Thrombosis in Martin has this year begun sequencing of the whole VWF gene in all our patients.

Most patients have had preliminary screening tests performed prior to arrival in our department, including CBC (complete blood count), PT (prothrombin time), and APTT (activated partial thromboplastin time). If these have not been performed, we include them with our workup, along with a thrombin time (TT) and fibrinogen level. Patients are diagnosed with type 3 VWD if there is undetectable VWF:Ag and VWF:RCo. The VWF:Ag and VWF:RCo are rechecked to confirm low levels before a definitive diagnosis is made. Type 1 VWD is diagnosed if the VWF:Ag and VWF:RCo are <30 IU/dL, with relative concordance (i.e., RCo/Ag >0.6, while those with VWF:Ag and VWF:RCo between 30 and 50 IU/dL with concordance are labelled as “deficiency of VWF”.

Additional tests, needed to distinguish and classify type 2 VWD (RCo/Ag <0.6), include VWF multimer analysis, VWF:CB, VWF-FVIII binding and ristocetin induced platelet aggregation (RIPA). The use of VWF:RCo and VWF:CB together improve the ability to detect type 2 variants. The VWF:CB is more accurate than the VWF:RCo in differentiating mild type 1 VWD from normal and in accurately assessing the level in severe types 1 or 3 disease. Type 2A VWD is identified by loss of high-molecular-weight multimers (HMW) VWF on multimer analysis. The laboratory finding of type 2B is the heightened RIPA with mild to moderate thrombocytopenia and the absence of HMW in plasma. Platelet type of VWD is often mistakenly diagnosed as type 2B VWD for the similarities between these two conditions. We hope that genetic testing in all our VWD patients
will prevent such errors. In type 2M VWD the VWF multimer distribution is normal, but decreased interaction of VWF with GP1bα; therefore, the VWF:RCo assay is reduced, leading to a low VWF:RCo/VWF:Ag ratio (<0.6). Type 2N is characterized with mildly reduced or normal levels of VWF:Ag and VWF:RCo and a normal multimers, but low plasma levels of FVIII (typically 5–40 U/dL), which result from the decreased plasma half-life of FVIII, which cannot bind to VWF. The definitive diagnosis of VWD type 2N is made by measuring the VWF:FVIII-binding capacity. Our VWD testing algorithm is shown in Figure 5.

**Treatment of VWD**

Treatment also follows guidelines outlined by the European Group on VWD, British Committee for Standards in Haematology and Slovak Society on Haemostasis and Thrombosis (11,12). There are two treatments of choice in VWD, non-concentrate therapies (desmopressin, tranexamic acid) and transfusion therapy with plasma-derived concentrates FVIII/VWF or concentrates containing either high purity VWF alone.

Most patients with type 1 VWD receive desmopressin as first line therapy. This may be administered intravenously or via intranasal spray. The exception is those patients with clearance defects (type 1C VWD) who may experience an initial rise in VWF:Ag and VWF:RCo in response to desmopressin but which then is rapidly cleared. In these patients, VWF-containing concentrates are chosen to achieve sustained therapeutic VWF levels. Some type 2 patients may also receive desmopressin for minor bleeds such as epistaxis, in particular type 2A patients.

Antifibrinolytic drugs are used for mucosal bleeding, particularly following tonsillectomy or tooth extraction or for women with menorrhagia. Oral administration is used for menorrhagia and post-tonsillectomy surgical prophylaxis, while topical administration is used for prevention or treatment of bleeding following tooth extraction. For minor dental procedures, treatment is given for 5–7 days and up to 14 days for multiple molar extractions; for tonsillectomy, antifibrinolytic therapy is generally continued for up to 14 days or until the eschar is shed.

VWF-containing concentrates (plasma-derived concentrates containing FVIII/VWF or high-purity VWF concentrate) are the primary therapy for patients with type 2 and type 3 VWD, as well as for the more severely affected type 1 patients. At this time, plasma derived concentrates are used exclusively. Haemate-P®, Willate® and Willfact® are licensed plasma-derived concentrates for treatment of VWD in the Slovakia.

Our local practice with replacement therapy during surgery, dental extraction and delivery or puerperium is identified in Table 2.

**Conclusions**

The prevalence of VWD in the Slovak Republic is
approximately 11.2 cases per 100,000 people, but this is probably still underestimated due to the fact that many patients, particularly those with mild disease, continue to obtain care through primary care physician. VWD diagnosis and management is best performed through hematology specialists familiar with the complexities of this condition, such as those in the hemophilia treatment centres. Improving the diagnosis of VWD is one of the goals of the study “Genetic Background and Hemostatic Changes in the Patients with VWD”, but much work remains to be done regarding treatment and quality of life for affected patients.

Acknowledgements

Funding: The study was supported by grants VEGA 1/0187/17.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

9. Zimmerman TS, Ratnoff OD, Powell AE. Immunologic differentiation of classic hemophilia (factor 8 deficiency) and von Willebrand’s disease, with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant against antihemophilic factor. J Clin Invest 1971;50:244-54.

Table 2 Our local practice with replacement therapy of VWD

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Major surgery</th>
<th>Minor surgery</th>
<th>Spontaneous bleeding episodes</th>
<th>Dental extractions</th>
<th>Delivery and puerperium</th>
</tr>
</thead>
<tbody>
<tr>
<td>Doses VWF/FVIII concentrate</td>
<td>loading dose 50–60 U/kg and maintenance dose 25 U/kg every 4 to 24 hours</td>
<td>30–60 U/kg daily or every other day</td>
<td>single or daily dose 20–60 U/kg</td>
<td>single dose 30 U/kg</td>
<td>50 U/kg daily or every other day</td>
</tr>
<tr>
<td>Therapeutic goal</td>
<td>through VWF:RCo and FVIII:C &gt;50 U/dL for 7–14 days</td>
<td>FVIII:C &gt;30 U/dL until healing is complete (2–4 days)</td>
<td>FVIII:C &gt;50 U/dL until bleeding stops (2–4 days)</td>
<td>FVIII:C &gt;50 U/dL for 12 hours</td>
<td>FVIII:C &gt;50 U/dL for 3–4 days</td>
</tr>
<tr>
<td>Safety parameter</td>
<td>do not exceed VWF:RCo 200 IU/dL or FVIII 250–300 IU/dL</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

VWD, von Willebrand disease; VWF, von Willebrand factor.

doi: 10.21037/aob.2018.01.03